



May 31, 2016

#34867  
Dr. Owatha L. Tatum  
Advanta Laboratories  
10935 CR 159, Suite 101  
Tyler, TX 75703

Dear Dr. Tatum:

I am writing concerning your personnel's performance in the analysis of the proficiency testing specimens that were recently sent to evaluate their capability to reliably analyze urine for drugs subject to abuse.

Based on a review of your analysts' performance, it has been determined that your laboratory can satisfactorily offer urine testing services to the extent specified below:

	Screening analysis only
	Confirmatory analysis only
<b>X</b>	<b>Screening and confirmatory analysis</b>
	Neither screening nor confirmatory analysis

In an e-mail to Julie Jumalon, dated May 9, 2016, she specified Advanta runs two drug panels; a 30 panel and a 75 panel. She indicated that some analytes overlapped on the panels. My advice was to run both instruments to properly identify all of the analytes in the PT, if there were different analytes in each of the panels. On future PTs, if you run both instruments, please report only one value for each analyte.

Your facility will be added to our list of laboratories approved to offer this service in accordance with regulations in Section 5.50 of Title 28, *Pennsylvania Code*, promulgated under the Commonwealth's Clinical Laboratory Act (35 P.S. §§2151-2165).

If you have any questions concerning the approval program or the status of your laboratory in it, please contact Chris Andrychowski by email at [candrychow@pa.gov](mailto:candrychow@pa.gov). I would like to take this opportunity to welcome you to the program and to wish you success in your testing activities.

Sincerely,

Jennifer Okraska, Director  
Division of Chemistry and Toxicology

Enclosures